Last mentioned: Mar 25, 2026
Expected Rebalancing
Passive funds expected to complete divestment of RNAM shares to match new index weights.
Earnings Previews
Seeking Alpha releases Q4 2025 previews for both Voyager and Zevra.
CFO Appointment
Zevra Therapeutics names Justin Renz as Chief Financial Officer.
S&P Index Deletion
S&P Dow Jones Indices removes RNAM from Global BMI and TMI benchmarks.
Novartis Deal Closure
Avidity finalizes agreement with Novartis, launching Atrium Therapeutics spinout.
Voyager Partnership Update
Voyager reports progress on TRACER platform milestones with Novartis.
Miplyffa Approval
Zevra receives FDA approval for arimoclomol in NPC.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution and platform validation. Investors are focused on Zevra's Miplyffa launch trajectory and Voyager's CNS-focused partnership revenue.
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices, effective March 2026. This technical deletion follows a major strategic milestone involving a deal closure with Novartis, signaling a period of significant structural transition for the biotech firm.
The Juvenile Idiopathic Arthritis (JIA) market is projected to expand at a 5.6% CAGR through 2036, reaching multi-billion dollar valuations driven by advanced biologic therapies. Major pharmaceutical players including Bristol-Myers Squibb and Novartis are positioned to capture significant share with next-generation treatments.
This page surfaces every story mentioning Novartis across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Novartis was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |